Positive topline data from Saturn-2 Phase 3 trial encourages Tarsus to file NDA in 2022
May 8th 2022TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
'Focus on Child Eye Health' initiative introduced by IAPB
April 9th 2022The International Agency for the Prevention of Blindness (IAPB) recently announced an expansion of their ‘Focus on Glaucoma’ and ‘Focus on Diabetes’ series with their new ‘Focus on Child Eye Health’ series in partnership with CooperVision.